Clinical trials: Sensory Processing Disorder
- Condition Sensory Processing Disorder
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Attention Deficit Hyperactivity Disorder
An Open-Label Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder
A single arm, open-label, phase 3 multicenter study to evaluate the effectiveness and tolerability of atomoxetine (given once daily, target dose 1.2 mg/kg/day), as perceived by patients, parents and physicians, and its impact on…
- Trial name
- NCT00191516
- Testing
- Atomoxetine
- Where
- Germany
- Volunteers
- 257 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
An Open-Label Study of Atomoxetine in Adolescents With Attention-Deficit/Hyperactivity Disorder
A single arm, open-label, phase 3 multicenter study to evaluate the effectiveness and tolerability of atomoxetine (given once daily, target dose 1.2 mg/kg/day), as perceived by patients, parents and physicians, and its impact on…
- Trial name
- NCT00191737
- Testing
- Atomoxetine
- Where
- 2 sites in Germany
- Volunteers
- 147 people
- Sponsor
- Eli Lilly and Company
Autism Spectrum Disorder (ASD)
Brain Stimulation and Sensory Integration in Children With ASD
The goal of this clinical trial is to find out if brain stimulation can help improve sensory integration in children ages 6 to 12 with autism spectrum disorder (ASD).
- Trial name
- NCT07182331
- Testing
- Continuous Theta Burst Stimulation to Bilateral DLPFC
- Where
- 2 sites in Kazakhstan
- Volunteers
- 40 people
- Sponsor
- Neurolab Plus